Cr Pharmaceutical

CR Pharmaceutical, a Pharmaceutical Preparation Manufacturing company headquartered in HK, reported total emissions of approximately 722,459,800 kg CO2e in 2024. This includes 175,023,130 kg CO2e from Scope 1 emissions and 547,436,670 kg CO2e from Scope 2 emissions.

In 2023, the company's total emissions were approximately 725,648,620 kg CO2e, comprising 170,536,140 kg CO2e from Scope 1 and 555,112,180 kg CO2e from Scope 2. In 2022, total emissions stood at about 722,459,800 kg CO2e, with Scope 1 emissions at 160,986,950 kg CO2e and Scope 2 emissions at 613,993,650 kg CO2e. For 2021, CR Pharmaceutical reported total emissions of approximately 648,394,790 kg CO2e, broken down into 121,763,870 kg CO2e from Scope 1 and 526,630,920 kg CO2e from Scope 2.

The company has set several climate commitments. CR Pharmaceutical aims to achieve carbon neutrality by 2050 for both Scope 1 and Scope 2 emissions. They also have near-term intensity targets, aiming to reduce carbon dioxide emission intensity by 10% in Scope 2 by the end of the 14th Five-Year Plan period (2025) compared to 2020 levels. Additionally, they target an 8% decrease in comprehensive energy consumption per RMB 10,000 of added value in Scope 1 by the end of the 14th Five-Year Plan period, against a 2020 baseline. Emissions and reduction targets are cascaded from China Resources Pharmaceutical Group Limited.